Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To investigate fluconazole susceptibility of Candida albicans from non-AIDS patients and to analyse the relationship between mutations in the ERG11 gene of these isolates and fluconazole resistance. METHODS: Four hundred and twenty-six clinical isolates of Candida species were collected. Fluconazole susceptibility was tested in vitro using microdilution and disc diffusion assays. The ERG11 genes of 23 isolates of C. albicans (8 susceptible and 15 resistant) and 6 type strains (4 susceptible and 2 resistant) were amplified in three overlapping regions of the gene and sequenced. RESULTS: Of the 426 isolates collected, 68.6% were C. albicans; however, only 5.1% were resistant to fluconazole. Eighteen silent mutations and 19 missense mutations were detected. There were six missense mutations only in resistant isolates or resistant type strains: (i) G487T (A114S) and T916C (Y257H) appeared simultaneously in 14 fluconazole-resistant isolates without any other mutation; these may be associated with resistance; (ii) T541C (Y132H) and T1559C (I471T) are known to contribute to fluconazole resistance; and (iii) C1567A (Q474K) or a novel mutation T1493A (F449Y) was identified but correlations with resistance have not been studied. CONCLUSIONS: In this survey, C. albicans is the major cause of candidiasis in non-AIDS patients, and some isolates that are resistant to fluconazole have G487T and T916C mutations in ERG11 that are associated with fluconazole resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Resistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461
Andes, D., Nett, J., Oschel, P., Albrecht, R., Marchillo, K., & Pitula, A. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.6023-6031.2004 · Cited by 389
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385
Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
Evolution of Drug Resistance in Experimental Populations of Candida albicans
Cowen, L. E., Sanglard, D., Calabrese, D., Sirjusingh, C., Anderson, J. B., & Kohn, L. M. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.6.1515-1522.2000 · Cited by 207
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166
St-Germain, G., Laverdière, M., Pelletier, R., Bourgault, A.-M., Libman, M., Lemieux, C., & Noël, G. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.949-953.2001 · Cited by 134
Cited by
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Contribution of Clinically Derived Mutations in ERG11 to Azole Resistance in Candida albicans
Flowers, S. A., Colón, B., Whaley, S. G., Schuler, M. A., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03470-14 · Cited by 294
Morio, F., Loge, C., Besse, B., Hennequin, C., & Le Pape, P. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.11.006 · Cited by 279
Cools, H. J., & Fraaije, B. A. (2013) · Pest Management Science · doi:10.1002/ps.3348 · Cited by 259
Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans
Xiang, M.-J., Liu, J.-Y., Ni, P.-H., Wang, S., Shi, C., Wei, B., Ni, Y.-X., & Ge, H.-L. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12042 · Cited by 197
Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00348-10 · Cited by 168
“E266D may exist in susceptible strains and is currently not understood to confer resistance (16, 17, 39).”
Confirmation of fifth Candida auris clade by whole genome sequencing
Spruijtenburg, B., Badali, H., Abastabar, M., Mirhendi, H., Khodavaisy, S., Sharifisooraki, J., Taghizadeh Armaki, M., de Groot, T., & Meis, J. F. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125349 · Cited by 164
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00303-10 · Cited by 165
Healey, K. R., Kordalewska, M., Jiménez Ortigosa, C., Singh, A., Berrío, I., Chowdhary, A., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01427-18 · Cited by 165
“Overall, the Colombian isolates were more susceptible to azoles than the Indian isolates, although we did identify 3 Colombian isolates that contained Y132F or K143R and exhibited higher MICs, as expected (Table 1).”
BackgroundInfluentialAzole Binding Properties of Candida albicans Sterol 14-α Demethylase (CaCYP51)
Warrilow, A. G. S., Martel, C. M., Parker, J. E., Melo, N., Lamb, D. C., Nes, W. D., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00587-10 · Cited by 112
“By building on this comprehensive investigation of clinically relevant azoles and their binding properties to purified wild-type CaCYP51, we are currently investigating the effects of CaCYP51 point mutations associated with azole resistance (9, 30, 32, 34, 47, 54, 56).”
BackgroundNishimoto, A. T., Sharma, C., & Rogers, P. D. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz400 · Cited by 102
Chen, L., Zhang, L., Xie, Y., Wang, Y., Tian, X., Fang, W., Xue, X., & Wang, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115007 · Cited by 63
Self-citationWang, H., Kong, F., Sorrell, T. C., Wang, B., McNicholas, P., Pantarat, N., Ellis, D., Xiao, M., Widmer, F., & Chen, S. C. (2009) · BMC Microbiology · doi:10.1186/1471-2180-9-167 · Cited by 58
Esfahani, A., Omran, A. N., Salehi, Z., Shams-Ghahfarokhi, M., Ghane, M., Eybpoosh, S., & Razzaghi-Abyaneh, M. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105696 · Cited by 30
Selected mechanisms of molecular resistance of Candida albicans to azole drugs
Gołąbek, K., Strzelczyk, J. K., Owczarek, A., Cuber, P., Ślemp-Migiel, A., & Wiczkowski, A. (2015) · Acta Biochimica Polonica · doi:10.18388/abp.2014_940 · Cited by 26
Expression pattern of drug-resistance genes ERG11 and TAC1 in Candida albicans Clinical isolates
Zare-Bidaki, M., Maleki, A., Ghanbarzadeh, N., & Nikoomanesh, F. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07878-0 · Cited by 15
Metadata
- Authors
- Xu, Y., Chen, L., & Li, C.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-04
- Volume
- 61
- Issue
- 4
- Pages
- 798-804
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2110850434
- Cited by
- 104
- References
- 9
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.